Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 50
Filter
Add more filters










Publication year range
1.
Vox Sang ; 111(3): 266-273, 2016 Oct.
Article in English | MEDLINE | ID: mdl-27232115

ABSTRACT

BACKGROUND AND OBJECTIVES: The solvent/detergent treatment enables effective and robust inactivation of all lipid-enveloped viruses, but also inactivates partly sensitive plasma proteins such as protein S. The aim of this study was to investigate the thrombin generation capacity of octaplasLG® , in particular focusing on the function of protein S in thrombin generation assay and the impact of assay settings. MATERIALS AND METHODS: Sixteen octaplasLG® batches and 32 units of single donor fresh frozen plasma (FFP) were investigated. For protein S, both functional activity and free antigen levels were measured. Thrombin generation assay was performed using two fluorogenic tests with different triggers. Finally, rotational thromboelastometry was performed. RESULTS: Mean protein S levels were lower in octaplasLG® , but a wider range of values was found for FFP. Clotting parameters and thrombin generation capacities overlapped between the two plasma groups as demonstrated using both thrombin generation assays and different triggers. Spiking studies with protein S-depleted plasma, human purified protein S or antibodies against protein S confirmed a correlation between protein S and thrombin generation capacity under specific assay conditions, especially in an assay with low tissue factor concentration. CONCLUSION: Correlation between protein S and thrombin generation capacity was demonstrated in the TGA. Due to higher variability in protein S content in the FFP group, overlapping haemostatic potentials of the two plasma groups were found.


Subject(s)
Detergents/pharmacology , Plasma/drug effects , Protein S/metabolism , Solvents/pharmacology , Thrombin/metabolism , Blood Coagulation/drug effects , Humans , Plasma/metabolism , Solvents/chemistry , Thrombelastography
2.
Vox Sang ; 103(3): 201-12, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22497541

ABSTRACT

BACKGROUND AND OBJECTIVES: Complement factor H (CFH) acts as major regulator of the alternative pathway of complement and its mutations and polymorphisms predispose to various human diseases. We aimed to develop a scalable purification process of CFH from human plasma fractions to supply a pathogen-safe and functional CFH concentrate. MATERIALS AND METHODS: Starting with intermediates of cold ethanol fractionation of plasma, CFH purification was performed with three chromatographic steps including solvent detergent treatment and nanofiltration. CFH functionality was tested by a haemolysis assay using sheep erythrocytes, by determining decay acceleration activity on C3 convertases and cofactor activity of C3b cleavage. CFH identity was confirmed by Western blot and mass spectrometry. RESULTS: Three scalable chromatographic steps highly purified full-length and native CFH from human plasma fractions. The purification process enabled the removal of truncated and dysfunctional CFH species, yielding a native CFH concentrate as demonstrated in sensitive functional in vitro assays. CONCLUSION: This novel process provides a pathogen-safe and functional CFH concentrate that can be produced on an industrial scale and is suitable for pre-/clinical studies.


Subject(s)
Complement Factor H/chemistry , Complement Factor H/isolation & purification , Animals , Centrifugation, Density Gradient , Complement C3/chemistry , Complement C3/genetics , Complement C3/metabolism , Complement Factor H/genetics , Complement Factor H/metabolism , Humans , Mass Spectrometry , Polymorphism, Genetic , Protein Binding , Sheep
3.
Vox Sang ; 102(4): 294-301, 2012 May.
Article in English | MEDLINE | ID: mdl-22070802

ABSTRACT

BACKGROUND: OctaplasLG(®) is a 2nd-generation virus inactivated pooled plasma for infusion. Prions are removed by the principle of chromatography, utilizing an affinity ligand gel (LG) developed for binding of prion proteins and their infectivity. The goal of this study was to verify, using the gold standard animal bioassay system, whether or not prion infectivity can be removed by the LG affinity step under conditions used in the routine manufacturing process. MATERIALS AND METHODS: Aliquots of pooled plasma were spiked with a microsomal/cytosolic (MIC) fraction of brain-derived hamster-adapted scrapie 263K and subjected to the OctaplasLG(®) manufacturing process. Validated Western blot tests and animal bioassays studies were performed to determine the logarithmic reduction factors (RF) and the prion infectivity binding capacity. RESULTS: Bioassay studies demonstrated different logarithmic RFs (i.e. 1·73 and 0·76 log(10)) at two different plasma-to-resin ratios, the latter one representing the actual manufacturing ratio of 100:1, which can be explained by the differences in the study design. However, both bioassay studies showed a reproducible and high prion infectivity binding capacity of ≥5·64 log(10) ID(50)/ml gel. CONCLUSION: Bioassay studies confirmed the capacity of the LG to bind brain-derived MIC prion proteins spiked into plasma. Even through infectivity was still detected following passage over the LG, this can be attributed to the high loads used in the study design, and the binding capacity of the LG still ensures a significant safety margin--binding the prion agents at the levels of prion infectivity that might be present in plasma and beyond.


Subject(s)
Chromatography, Affinity/methods , Prions/isolation & purification , Animals , Blood Transfusion/standards , Brain , Chromatography, Affinity/standards , Cricetinae , Plasma , Prions/analysis , Protein Binding
4.
J Thromb Haemost ; 8(10): 2216-23, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20727070

ABSTRACT

UNLABELLED: BACKGROUND, OBJECTIVES AND METHODS: An accurate, sensitive and precise assay for reliable determination of the ristocetin cofactor activity of von Willebrand factor (VWF:RCo) in plasma and von Willebrand Factor (VWF)-containing concentrates has been evaluated. The assay is based on a commercially available automated protocol with modifications including a combination of adding additional ristocetin and the use of two calibration curves for the high and low measuring ranges. RESULTS: Addition of extra ristocetin resulted in improved measurement of VWF recoveries from various VWF-containing concentrates that were underestimated using the standard automated protocol. The modifications resulted in improved assay performance over an extended measuring range (2.00-0.03 IUmL(-1) ). Accuracy was tested using VWF deficiency plasma spiked with the 1st international standard (IS) for VWF concentrate. Seven dilutions, ranging from 1.80 to 0.05IUmL(-1) , were analyzed and resulted in measured concentrations between 80% and 100% of the assigned potency of the standard. Linearity was determined from the regression plot of the same concentrate dilutions and resulted in a correlation coefficient of 0.998. The repeatability, expressed as coefficient of variation, was 2% in the normal range (0.90IUmL(-1) ) and 8% at the level of 0.05IUmL(-1) . The corresponding reproducibility results were 2% and 15% at the normal and low measuring ranges, respectively. CONCLUSIONS: Analysis of patients with von Willebrand disease (VWD) indicates that the modified automated BCS(®) protocol has a superior discrimination power compared with the standard protocol. This is especially true in samples with low VWF, as in patients with type 3 VWD.


Subject(s)
Blood Coagulation Tests/instrumentation , Ristocetin/blood , von Willebrand Diseases/blood , Algorithms , Automation , Calibration , Humans , Reference Standards , Reproducibility of Results , Temperature , von Willebrand Diseases/diagnosis , von Willebrand Factor/analysis
5.
Vox Sang ; 97(3): 226-33, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19548963

ABSTRACT

BACKGROUND AND OBJECTIVES: A new chromatographic step for the selective binding of abnormal prion protein (PrP(Sc)) was developed, and optimization for PrP(Sc) capture was achieved by binding to an affinity ligand attached to synthetic resin particles. This step was implemented into the manufacturing process of the solvent/detergent (S/D)-treated biopharmaceutical quality plasma Octaplas to further improve the safety margin in terms of risk for variant Creutzfeldt-Jakob disease (vCJD) transmission. MATERIALS AND METHODS: Intermediates and Octaplas final container material, spiked with hamster brain-derived PrP(Sc)-containing fractions, were used for experiments to establish the feasibility of introducing this novel chromatography step. The binding capacity per millilitre of ligand gel was determined under the selected manufacturing conditions. In addition, the specificity of the ligand gel to bind PrP(Sc) from human sources was investigated. A validated Western blot test was used for the identification and quantification of PrP(Sc). RESULTS: A reduction factor of > or = 3.0 log(10) could be demonstrated by Western blotting, utilizing the relevant Octaplas matrix from manufacturing. In this particular cell-free plasma solution, the PrP(Sc) binding capacity of the selected gel was very high (> or = 6 log(10) ID(50)/ml, equivalent to roughly 10 log(10) ID(50)/column at manufacturing scale). The gel binds specifically PrP(Sc) from both animal (hamster and mouse) and human (sporadic and variant CJD) sources. CONCLUSION: This new single-use, disposable PrP(Sc)-harvesting gel ensures a very high capacity in terms of removing the pathogenic agent causing vCJD from the new generation OctaplasLG, in the event that prions can be found in plasma from donors incubating the disease and thereby contaminating the raw material plasma used for manufacturing.


Subject(s)
Blood-Borne Pathogens/isolation & purification , Chromatography, Affinity/methods , Detergents/pharmacology , Plasma/drug effects , PrPSc Proteins/isolation & purification , Resins, Synthetic/pharmacology , Solvents/pharmacology , Sorption Detoxification/methods , Animals , Blotting, Western , Creutzfeldt-Jakob Syndrome/prevention & control , Cricetinae , Feasibility Studies , Gerstmann-Straussler-Scheinker Disease , Humans , Mesocricetus , Mice , Pilot Projects , PrPSc Proteins/analysis , Protein Binding , Reproducibility of Results , Scrapie , Time Factors
6.
Vox Sang ; 97(3): 219-25, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19392784

ABSTRACT

BACKGROUND AND OBJECTIVES: A new chromatographic step for the selective binding of pathological prion proteins (PrP(Sc)) to an affinity ligand, developed and optimized for PrP(Sc) capture and attached to synthetic resin particles (PRDT, USA; ProMetic BioSciences Ltd, Isle of Man, UK) was implemented into the manufacturing process of the solvent/detergent (S/D) treated biopharmaceutical quality plasma Octaplas. MATERIALS AND METHODS: Pilot batches of Octaplas with the implemented chromatographic step [labelled as OctaplasLG (ligand gel)] were manufactured by Octapharma PPGmbH, Vienna, Austria. The biochemical quality was compared directly after manufacturing as well as after 18 months storage. All samples were tested on global coagulation parameters, fibrinogen levels, activities of coagulation factors and protease inhibitors, ADAMTS13 levels, as well as markers of activated coagulation and fibrinolysis. In addition, von Willebrand factor multimeric analysis was performed. RESULTS: The incorporation of this novel chromatography into the large-scale routine manufacturing process was shown to be technically feasible and the performance of the column was assessed to be excellent. The biochemical studies showed that Octaplas and OctaplasLG produced without and with the new column, respectively, demonstrate an identical biochemical quality. OctaplasLG remained stable over a period of 18 months stored frozen. A parallel reduction of the S/D virus inactivation step from 4-4.5 to 1-1.5 h led to significantly higher activities of plasmin inhibitor. CONCLUSION: The studies confirmed that the affinity ligand chromatography under the developed conditions can be introduced into the Octaplas manufacturing process, as a mean to reduce potentially present PrP(Sc), without hampering the proven quality of this product.


Subject(s)
Blood-Borne Pathogens/isolation & purification , Chromatography, Affinity/methods , Detergents/pharmacology , Plasma/drug effects , PrPSc Proteins/isolation & purification , Resins, Synthetic/pharmacology , Solvents/pharmacology , Sorption Detoxification/methods , ADAM Proteins/blood , ADAMTS13 Protein , Blood Coagulation Tests , Blood Preservation , Feasibility Studies , Fibrinogen/analysis , Humans , Pilot Projects , Protein Binding , Thrombelastography , Thrombin/biosynthesis , Time Factors , von Willebrand Factor/analysis , von Willebrand Factor/chemistry
7.
Vox Sang ; 94(1): 48-55, 2008 Jan.
Article in English | MEDLINE | ID: mdl-18021185

ABSTRACT

BACKGROUND AND OBJECTIVES: The most common way to thaw frozen coagulation-active plasma products for transfusion is the use of a water bath with good circulation at 30-37 degrees C. The aim of this study was to perform an extensive biochemical characterization of the pharmaceutically licenced solvent/detergent-treated plasma, Octaplas, thawed using the SAHARA-III dry tempering system from the company Sarstedt GmbH, Austria. A regular water bath was used in parallel for comparison. MATERIALS AND METHODS: Six batches Octaplas with different blood groups were thawed in a water bath or using the SAHARA-III dry tempering system in parallel. Thawed plasma was investigated on screening tests for blood coagulation, as well as on the activities of important coagulation factors and protease inhibitors. In addition, markers of activated coagulation and fibrinolysis were tested and von Willebrand factor multimeric analysis was performed. RESULTS: There were neither significant differences in the blood coagulation parameters, coagulation factors, protease inhibitors, nor of markers of activated coagulation and fibrinolysis when Octaplas thawed by the two different methods was tested. The von Willebrand factor analyses showed no influence on the overall profile of the multimeric pattern when using the SAHARA-III dry tempering system. CONCLUSION: Octaplas can be thawed using the SAHARA-III dry tempering system without any negative influences on the demonstrated quality of this product. The SAHARA-III dry tempering system enables standardized thawing and warming procedure. Furthermore, tempering of Octaplas in the emergency unit or operating theatre, where no water baths can be utilized, is safe and can be fully endorsed.


Subject(s)
Blood Coagulation Factors/analysis , Blood Coagulation Factors/standards , Plasma/chemistry , Blood Coagulation , Fibrinolysis , Freezing , Humans , Plasminogen/analysis , Protease Inhibitors/analysis , Quality Control , von Willebrand Factor/analysis
9.
Vox Sang ; 92(3): 206-12, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17348869

ABSTRACT

BACKGROUND AND OBJECTIVES: The pathomechanism of thrombotic thrombocytopenic purpura (TTP) and atypical haemolytic uraemic syndrome (aHUS) is associated with a severe deficiency of ADAMTS13 and factor H. The aim of this study was to quantify the levels of ADAMTS13 and factor H in the pharmaceutically licensed plasma for transfusion, Octaplas, and the universally applicable plasma, Uniplas (development product, working title). Furthermore, Octaplas batches of blood groups A, B, O, AB, and plasmas derived from different sources were compared. MATERIALS AND METHODS: Twenty-four Octaplas and three Uniplas batches were selected for the study. ADAMTS13 activities were measured by fluorescence resonance energy transfer assay, ADAMTS13 antigen levels were quantified using enzyme-linked immunosorbent assay test kit, while factor H antigen levels were detected using radial immunodiffusion (RID) methods. In addition, von Willebrand factor (vWF) multimeric analyses were performed. RESULTS: Both Octaplas, produced from US and European plasma of different blood groups, and Uniplas contain ADAMTS13 antigen and activity levels as well as factor H concentrations at normal levels without significant differences. In addition, Octaplas and Uniplas show a vWF multimeric pattern comparable to normal plasma. CONCLUSION: The study revealed that Octaplas and Uniplas contain normal levels of ADAMTS13 at low batch-to-batch variations. Therefore, both products can substitute the missing or neutralized protease activity in TTP patients and thereby limit vWF-dependent (platelet-related) thrombosis. In addition, both plasma products contain factor H at a physiological level, and, thus can be used efficiently in the treatment of aHUS patients, which have been shown to benefit from plasma administration.


Subject(s)
ADAM Proteins/analysis , Blood Component Transfusion , Complement Factor H/analysis , Plasma/chemistry , ADAMTS13 Protein , Hemolytic-Uremic Syndrome/therapy , Humans
10.
Biologicals ; 34(4): 281-8, 2006 Dec.
Article in English | MEDLINE | ID: mdl-16500114

ABSTRACT

This study summarises the biochemical and functional properties of a new generation plasma-derived, double virus inactivated von Willebrand Factor/Factor VIII (VWF/FVIII) concentrate, Wilate, targeted for the treatment of both von Willebrand disease (VWD) and haemophilia A. The manufacturing process comprises two chromatographic steps based on different performance principles, ensuring a high purity of the concentrate (mean specific activity in 15 consecutive production batches: 122 IU FVIII:C/mg total protein) and, thus, minimising the administered protein load to the patient (specification: < or = 15 mg total protein per 900 IU Wilate). The optimised solvent/detergent (S/D) treatment and prolonged terminal dry-heat (PermaHeat) treatment of the lyophilised product at a specified residual moisture (RM) provide two mechanistically independent, effective and robust virus inactivation procedures for enveloped viruses and one step for non-enveloped viruses. These process steps are aggressive enough to inactivate viruses efficiently, but yet gentle enough to maintain the structural integrity and function of the VWF and FVIII molecules, as proven by state-of-the-art assays covering the diverse features of importance. The VWF multimeric pattern is close to the one displayed by normal plasma, with a consistent content of more than 10 multimers, but a relatively lower portion of the very high multimers. The multimeric triplet structure is normal, underlining the gentle and effective manufacturing process, which does not require the addition of protein stabilisers at any step. The balanced activity ratio of VWF to FVIII is close to that of plasma from healthy subjects, rendering Wilate suitable also for the safe and effective treatment of patients with VWD.


Subject(s)
Factor VIII/isolation & purification , Factor VIII/physiology , HIV-1/physiology , Virus Inactivation , von Willebrand Factor/isolation & purification , von Willebrand Factor/physiology , Blood Proteins/physiology , Factor VIII/chemistry , HIV-1/isolation & purification , Humans , Safety , von Willebrand Factor/chemistry
11.
Acta Med Austriaca ; 29(3): 89-92, 2002.
Article in English | MEDLINE | ID: mdl-12168569

ABSTRACT

Leukocyte-endothelial cell interaction and microvascular perfusion failure are characteristic deteriorations of the microcirculation in endotoxaemia and are known to play a crucial role in the development of septic multiple organ dysfunction. Recent studies have indicated that antithrombin III treatment is capable of significantly ameliorating these microcirculatory disorders. Endothelial cells have important anticoagulant systems, including the heparan sulfate-antithrombin system. Antithrombin III stimulates prostacyclin generation in endothelial cells by interacting with heparan sulfate of endothelial cells and inhibits cytokine and tissue factor production in endothelial cells and monocytes. Similar mechanisms may be involved in cellular actions of antithrombin III causing desensitization of chemoattractant receptors of leukocytes by activating the heparan sulfate proteoglycan, syndecan-4. Thus, antithrombin III might be among the useful agents for treating coagulation abnormalities associated with sepsis or other inflammation because it inhibits not only coagulation but also downregulation of anticoagulant activities of endothelial cells and affects leukocyte activation.


Subject(s)
Anti-Inflammatory Agents , Antithrombins/physiology , Antithrombin III/pharmacology , Antithrombin III/physiology , Antithrombins/pharmacology , Blood Coagulation/drug effects , Blood Coagulation/physiology , Endothelium, Vascular/physiology , Endothelium, Vascular/physiopathology , Humans , Leukocytes/drug effects , Leukocytes/physiology , Sepsis/physiopathology
12.
Blood Coagul Fibrinolysis ; 12(5): 375-83, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11505081

ABSTRACT

Plasma samples of 189 healthy subjects were investigated for antigen levels of the recently reported factor VII- and single-chain plasminogen activator-activating protease (FSAP) and the corresponding pro-urokinase activating potencies. While the age of donors had no significant effect on the investigated parameters, female plasmas revealed a trend to higher antigen contents and activity levels. Surprisingly, as much as 9% of all samples contained significantly reduced single-chain urinary plasminogen activator activating potential, whereas antigen concentrations were normal. Additionally, 1% of the plasmas was found to decrease in both FSAP antigen and activity contents. FSAP of three subjects displaying reduced activities throughout a follow-up period of 6 months were purified from plasmas and were characterized. As compared with pool plasma derived FSAP, investigation of the individual preparations confirmed their reduced potency to activate pro-urokinase. However, factor VII activation was not affected. It is speculated that the FSAP binding site for single-chain plasminogen activators is affected, potentially by as yet unknown polymorphism(s) or mutation(s).


Subject(s)
Serine Endopeptidases/blood , Serine Endopeptidases/pharmacology , Urokinase-Type Plasminogen Activator/metabolism , Adult , Age Factors , Aged , Blotting, Western , Electrophoresis, Polyacrylamide Gel , Enzyme-Linked Immunosorbent Assay , Female , Humans , Male , Middle Aged , Recombinant Proteins/drug effects , Recombinant Proteins/metabolism , Serine Endopeptidases/chemistry , Sex Factors , Time Factors , Urokinase-Type Plasminogen Activator/chemistry , Urokinase-Type Plasminogen Activator/drug effects
13.
J Chromatogr A ; 924(1-2): 307-13, 2001 Jul 27.
Article in English | MEDLINE | ID: mdl-11521878

ABSTRACT

The characterisation of proteins is still one of the most challenging analytical tasks in modern bioanalysis. Due to the complex structure of proteins, several analytical techniques are often required to get sufficient information. Antithrombin III (AT III), a high-molecular-mass plasma glycoprotein which is an important protease inhibitor and the main modulator of thrombin activity, circulates in plasma in two isoforms, the so-called AT III-alpha (90-95%) and -beta (5-10%). Micellar electrokinetic chromatography was used to analytically separate these AT III variants, which differ in their affinity to the polysaccharide heparin.


Subject(s)
Antithrombin III/isolation & purification , Chromatography, Micellar Electrokinetic Capillary/methods , Antithrombin III/metabolism , Heparin/metabolism , Humans
14.
Eur J Biochem ; 268(13): 3789-96, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11432747

ABSTRACT

Structural and biological characteristics of a recently described plasma serine protease, which displayed factor VII as well as pro-urokinase-activating properties in vitro, indicated a dual role for this factor VII-activating protease (FSAP) in hemostasis. Only the active protease (two-chain FSAP) has been isolated from plasma and from a prothrombin complex concentrate, whereas activators of the proenzyme have not been identified so far. After purification of the FSAP proenzyme from cryo-poor plasma by adsorption to an immobilized mAb and subsequent ion-exchange chromatography, activation to generate two-chain FSAP was followed by a direct chromogenic assay as well as by the ability of two-chain FSAP to activate pro-urokinase. Purified single-chain FSAP underwent autoactivation leading to the typical protease two-chain pattern and subsequent degradation products, as demonstrated by Western-blotting analysis using a site-specific mAb. This autoactivation was significantly enhanced in the presence of heparin, whereas Ca2+ ions stabilized single-chain FSAP (the proenzyme) resulting in slower autoactivation kinetics. Correspondingly, the heparin-augmented reaction, which was associated with autodegradation particularly of the protease domain, was slowed down by co-incubation with Ca2+. Of the other proteases and cofactors tested, only urokinase (uPA) was able to generate the typical two-chain FSAP pattern. Studies with different forms of uPA suggest that the catalytic activity of pro-urokinase/uPA is needed to activate single-chain FSAP, indicating that it is the only hemostatic protease that can act as a physiological activator of FSAP.


Subject(s)
Enzyme Precursors/metabolism , Factor VII/metabolism , Serine Endopeptidases/metabolism , Blood Coagulation , Chromatography, Affinity , Chromatography, Ion Exchange , Electrophoresis, Polyacrylamide Gel , Enzyme Activation , Enzyme Precursors/chemistry , Enzyme Precursors/isolation & purification , Enzyme-Linked Immunosorbent Assay , Fibrinolysis , Glycosylation , Humans , Kinetics , Molecular Weight , Monosaccharides/analysis , Protein Processing, Post-Translational , Serine Endopeptidases/chemistry , Serine Endopeptidases/isolation & purification
15.
Crit Care Med ; 29(1): 134-9, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11176173

ABSTRACT

OBJECTIVE: To investigate the effects of antithrombin on lipopolysaccharide (LPS)-induced tissue factor and interleukin-6 (IL-6) production in three different in vitro cellular systems: whole blood, human umbilical vein endothelial cells, and mononuclear cells. DESIGN AND SETTING: Laboratory in vitro study of the effects of antithrombin on procoagulant activity and cytokine release by LPS-stimulated endothelial and peripheral blood cells. SUBJECTS: In vitro whole blood, isolated human umbilical vein endothelial cell, and mononuclear cell cultures. INTERVENTIONS: Addition of antithrombin to LPS-treated whole blood, human umbilical vein endothelial cells, and mononuclear cells. MEASUREMENT AND MAIN RESULTS: Citrated whole blood, isolated human umbilical vein endothelial cells, or mononuclear cells were stimulated with LPS for 4-6 hrs in the presence or absence of antithrombin. Tissue factor activity was estimated by a tissue factor-dependent clotting or chromogenic assay and IL-6 was measured by specific ELISA. Antithrombin was found to inhibit tissue factor and IL-6 production in all three systems in a dose-dependent manner (0-40 IU/mL). Flow-through fractions of immunoadsorbed antithrombin concentrate were found to be ineffective. Five different batches of the same antithrombin concentrate were tested and the inhibitory activity was found to be consistent throughout all batches. Up to 40 microM of recombinant hirudin, a specific thrombin inhibitor, did not inhibit the production of tissue factor or IL-6 in either of the three cell systems, suggesting that the observed inhibition by antithrombin was not due solely to its ability to inhibit thrombin. CONCLUSIONS: Apart from the inhibition of thrombin and other activated clotting factors, antithrombin may also down-regulate the cellular expression of proinflammatory cytokines. Consequently, antithrombin concentrates may have value in the treatment of sepsis-induced disseminated intravascular coagulation.


Subject(s)
Antithrombins/immunology , Interleukin-6/biosynthesis , Sepsis/physiopathology , Thromboplastin/biosynthesis , Blood/metabolism , Cells, Cultured , Endothelium, Vascular/metabolism , Hirudins/immunology , Humans , In Vitro Techniques , Leukocytes, Mononuclear/metabolism , Lipopolysaccharides/pharmacology , Umbilical Veins/cytology
16.
Blood ; 97(4): 1079-85, 2001 Feb 15.
Article in English | MEDLINE | ID: mdl-11159540

ABSTRACT

The serpin antithrombin III (AT III) is reported to have hemostasis-regulating and anti-inflammatory properties. To determine its ability to influence thrombin-independent leukocyte responses, the direct effects of the AT III concentrate Kybernin P and a monoclonal antibody-purified AT III on neutrophil migration were studied. Chemotactic activity of human neutrophils isolated from the blood of healthy donors was determined in modified Boyden microchemotaxis chambers, and binding studies were performed according to standard experimental protocols. Preincubation in vitro of neutrophils with Kybernin P or immune-adsorbed AT III significantly deactivated migration toward fMet-Leu-Phe, or interleukin-8 (IL-8), in a concentration-dependent manner. In the absence of additional attractants, neutrophils exhibited a migratory response toward gradients of AT III preparations. True chemotaxis was confirmed in checkerboard assays. Analyses revealed that the AT III heparin-binding site interacts with neutrophil membrane-associated heparan sulfate proteoglycan receptors. Mechanisms of intracellular signaling differed; the deactivation of IL-8-induced chemotaxis resulted from tyrphostin-sensitive interactions of AT III-signaling with the IL-8 signal transduction pathway, whereas AT III-induced chemotaxis involved protein kinase C and phosphodiesterases. Signaling similarities between AT III and the proteoglycan syndecan-4 may suggest the binding of AT III to this novel type of membrane receptor. Under physiological conditions, AT III may prevent neutrophils from premature activation. Moreover, the systemic administration of AT III concentrate could have beneficial effects in combating systemic inflammation.


Subject(s)
Antithrombin III/pharmacology , Antithrombins/pharmacology , Chemotaxis, Leukocyte/drug effects , Heparan Sulfate Proteoglycans/physiology , Neutrophils/drug effects , Antibodies, Monoclonal/immunology , Antithrombin III/drug effects , Antithrombin III/immunology , Antithrombin III/isolation & purification , Binding Sites , Cells, Cultured/drug effects , Heparin Lyase/pharmacology , Heymann Nephritis Antigenic Complex , Hirudins/pharmacology , Humans , Immunosorbent Techniques , Interleukin-8/metabolism , Interleukin-8/pharmacology , Leukocyte Common Antigens/metabolism , Leukocyte Elastase/pharmacology , Membrane Glycoproteins/metabolism , Membrane Glycoproteins/pharmacology , N-Formylmethionine Leucyl-Phenylalanine/antagonists & inhibitors , N-Formylmethionine Leucyl-Phenylalanine/pharmacology , Neutrophils/cytology , Oligosaccharides/antagonists & inhibitors , Oligosaccharides/physiology , Peptide Hydrolases/pharmacology , Proteoglycans/metabolism , Receptors, Interleukin-8A/antagonists & inhibitors , Receptors, Interleukin-8A/immunology , Receptors, Interleukin-8A/metabolism , Receptors, Interleukin-8B/antagonists & inhibitors , Receptors, Interleukin-8B/immunology , Receptors, Interleukin-8B/metabolism , Sialyl Lewis X Antigen , Signal Transduction , Structure-Activity Relationship , Syndecan-4
17.
Haemostasis ; 29(5): 292-9, 1999.
Article in English | MEDLINE | ID: mdl-10754382

ABSTRACT

A serine protease isolated from plasma sharing structural characteristics with a hepatocyte growth factor activator-like protease has been demonstrated recently to activate FVII. Accordingly, it was named 'FVII activator'. Until now an impact of this protease on the fibrinolytic system has not been reported. We islolated the protease from cryo-poor plasma by subsequent ion exchange chromatography and adsorption to immobilized heparin and/or aprotinin. Incubation of single-chain plasminogen activators (sc-PAs) with the FVII activator revealed significant activation of urokinase sc-PA (scu-PA) and tissue sc-PA (sct-PA) in vitro. It was enhanced in the presence of calcium and heparin. Compared to kallikrein, a more efficient activation of scu-PA was observed, whereas sct-PA appeared to be a poorer substrate for the FVI activator. At low protease concentrations and in the presence of heparin the scu-PA activation was comparable to plasmin. Employing recalcified whole blood thrombelastography, the lysis of initially formed fibrin was observed after addition of a combination of scu-PA and the FVII activator, whereas the scu-PA alone had a negligible effect at the concentration used. The study results as presented demonstrate that the FVII activator is a potent activator of sc-PAs in vitro. Whether it plays a physiological role in fibrinolysis deserves further investigation. Its comparatively high affinity to heparin assumes a function in cell surface or matrix events.


Subject(s)
Factor VII/metabolism , Serine Endopeptidases/pharmacology , Tissue Plasminogen Activator/metabolism , Blood Coagulation Factors/metabolism , Blood Coagulation Tests , Chromogenic Compounds/metabolism , Enzyme Activation/drug effects , Factor VII/drug effects , Factor VIIa/drug effects , Factor VIIa/metabolism , Fibrinolysis/drug effects , Humans , Oligopeptides/metabolism , Serine Endopeptidases/isolation & purification , Serine Endopeptidases/metabolism , Serine Proteinase Inhibitors/metabolism , Urokinase-Type Plasminogen Activator/metabolism
18.
Blood Coagul Fibrinolysis ; 10(8): 471-9, 1999 Dec.
Article in English | MEDLINE | ID: mdl-10636458

ABSTRACT

An activity detected in a prothrombin complex concentrate, termed 'thrombin-like' due to its amidolytic properties, was recently reported by another working group. This serine-protease revealed partial structural homology with a 'hepatocyte growth factor activator'. An impact of this protease on coagulation has not yet been described. The protease was isolated from plasma fractions by ion exchange chromatography and adsorption to immobilized heparin and/or aprotinin. Clotting tests including the FVIIa-rTF assay were performed employing coagulometry. A monoclonal antibody-derived F(ab')2 to FVIII was used to investigate the FVIII bypassing activity (FEIBA). The identity of the-protease with the so-called 'thrombin-like' protease was supported by sequencing of the amino-termini. Its amidolytic activity was significantly enhanced in the presence of calcium and/or heparin. Incubation with purified FVII revealed the generation of FVIIa, but was prevented by pre-incubation of the protease with aprotinin. In contrast, purified FV and FVIII were inactivated. Studying coagulation parameters, clotting times like plasma recalcification times and the prothrombin times were found to be shortened by addition of the protease. Employing a FVIII-inhibitory F(ab')2 and enhancing clotting times significantly, FEIBA of the protease was found. We demonstrated that the isolated protease activates FVII independent of tissue factor. Net acceleration of coagulation was found in several global clotting assays resulting in an in vitro FEIBA. The physiological relevance of these findings deserves further investigation.


Subject(s)
Endopeptidases/isolation & purification , Factor VII/metabolism , Amidohydrolases/antagonists & inhibitors , Amidohydrolases/drug effects , Amidohydrolases/metabolism , Aprotinin/metabolism , Blood Coagulation/drug effects , Cations, Divalent/pharmacology , Endopeptidases/chemistry , Endopeptidases/metabolism , Factor VIII/metabolism , Factor VIIa/biosynthesis , Heparin/pharmacology , Humans , Sequence Analysis, Protein , Thromboplastin , Whole Blood Coagulation Time
19.
Semin Thromb Hemost ; 24(2): 175-81, 1998.
Article in English | MEDLINE | ID: mdl-9579640

ABSTRACT

Three commercial prothrombin complex concentrates (PCC) were compared in vitro. Differences in the activities or contents, respectively, of the PCC factors FII, FVII, FIX, FX and the proteins C, S, and Z (antigen) in particular were found. Global tests of activated factors did not reveal marked differences between the products. Neither free thrombin nor elevated levels of activated FX were detected. In contrast, analyses of FVIIa, of residual amidolytic activities, and of concentrations of unwanted ingredients demonstrated considerable differences between the products. While antithrombin III was detected only in two of three concentrates, heparin was found in all PCCs but in markedly different concentrations. Although the homogeneity of the products has been clearly improved in comparison with former comparative investigations, the products can be distinguished by their compound profile and by a couple of in vitro assays.


Subject(s)
Biological Products/chemistry , Blood Coagulation Factors/analysis , Blood Coagulation Factors/isolation & purification , Blood Coagulation Tests , Chromogenic Compounds/metabolism , Enzyme Activation , Enzyme-Linked Immunosorbent Assay , Factor IX/analysis , Factor VII/analysis , Factor X/analysis , Factor Xa/metabolism , Humans , Oligopeptides/metabolism , Prothrombin/analysis , Quality Control , Safety
20.
Haemostasis ; 26(3): 170-7, 1996.
Article in English | MEDLINE | ID: mdl-8738592

ABSTRACT

Synovial fluids drawn from joints of patients suffering from rheumatoid arthritis were investigated for their concentrations of proteins and activation markers of the complement, coagulation and fibrinolytic systems. A broad spectrum of plasmatic inhibitors and other hemostatic proteins were detectable by immunologic assays. Compared to normal plasma concentration ranges, levels of alpha 2-antiplasmin, antithrombin III, heparin-cofactor II, factor H, alpha 2-macroglobulin, inter-alpha-trypsin inhibitor, fibrinogen and particularly high molecular weight kininogen were found to be decreased when corrected for total protein content. However, highly elevated levels of C-reactive protein, factor XIII, PMN-elastase, prothrombin fragment F1+2, thrombin-antithrombin III, plasmin-antiplasmin and terminal complement-complexes as well as C5a were determined. Eight and 24 hours after induction of chemical synoviorthesis, a general increase in most of the parameters was observed. Statistically significant alterations were found for C1-inhibitor, factor H, alpha 1-antitrypsin, inter-alpha-trypsin inhibitor, factor XIII, protein C, thrombin-antithrombin III complexes and C5a.


Subject(s)
Arthritis, Rheumatoid/metabolism , Blood Coagulation Factors/analysis , Blood Proteins/analysis , Fibrinolysis/physiology , Hemostasis/physiology , Synovial Fluid/chemistry , Biomarkers/chemistry , Complement System Proteins/analysis , Female , Humans , Injections, Intra-Articular , Knee Joint/drug effects , Male , Synovial Membrane/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...